Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 24;63(7):e00079-19.
doi: 10.1128/AAC.00079-19. Print 2019 Jul.

Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury

Affiliations

Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury

Gwendolyn M Pais et al. Antimicrob Agents Chemother. .

Abstract

Urinary biomarkers are superior to serum creatinine for defining onset and extent of kidney injury. This study classifies the temporal predictive ability of biomarkers for vancomycin-induced kidney injury (VIKI) as defined by histopathologic damage. Male Sprague-Dawley rats (n = 125) were randomized to receive 150 to 400 mg/kg of body weight/day vancomycin via once or twice daily intraperitoneal injection over 1, 3, or 6 days. Urine was collected once during the 24 h prior to euthanasia or twice for rats treated for 6 days. Receiver operating characteristic (ROC) curves were employed to assess the urinary biomarker performances of kidney injury molecule 1 (KIM-1), clusterin, osteopontin (OPN), cystatin C, and neutrophil gelatinase-associated lipocalin (NGAL) to predict histopathologically defined VIKI (using a national standard pathological assessment scheme from hematoxylin and eosin stained kidneys). Urinary KIM-1, clusterin, and OPN outperformed cystatin C and NGAL with regard to sensitivity and specificity. For the earliest injury, urinary KIM-1 (area under the receiver operating characteristic curve [AUC], 0.662; P < 0.001) and clusterin (AUC, 0.706; P < 0.001) were the most sensitive for predicting even low-level histopathologic damage at 24 h compared to NGAL. KIM-1 and clusterin are the earliest and most sensitive predictors of VIKI. As injury progresses, KIM-1, clusterin, and OPN best define the extent of damage.

Keywords: KIM-1; PK/PD; PK/TD; biomarker; histopathology; injury; kidney; toxicity; urinary; vancomycin.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(a) Flow chart for animal dosing. TDD, total daily dose; q12h, every 12 h; *, missed second dose on day 6. (b) Timeline of the experiments.
FIG 2
FIG 2
Representative photomicrographs of hematoxylin and eosin (H&E) stained rat kidney sections. (a and d) Normal histology of kidney tissue in control rats administered normal saline intraperitoneally once daily for 24 h (×40) and 72 h (×200), respectively. (b) Classic wedge-shaped region of infarct (asterisk, ×20) with (c) necrosis of tubular epithelium and portions of glomeruli (arrowheads, ×100) in cortex of rats treated with vancomycin 200 mg/kg once daily for 24 h. (e) Multiple tubules containing sloughed cells (arrowheads) in cortex of rats treated with vancomycin 400 mg/kg once daily for 72 h (×100).
FIG 3
FIG 3
ROC analysis for vancomycin studies. (a to d) ROC curves demonstrating sensitivity and specificity of urinary KIM-1, clusterin, OPN, cystatin C, and NGAL with respect to a histopathology grade of ≥1 on day 1 (a) and on day 3 (b) and a histopathology grade of ≥2 on day 1 (c) and on day 3 (d). Animal numbers, n; histopath = 0, n = 32; histopath ≥ 1, n = 93; histopath ≥ 2, n = 37.
FIG 4
FIG 4
Schematic of the nephron (51) and urinary biomarker colocalization with injury (21). Bolded biomarker will aid in discretizing injury location.

References

    1. Pakyz AL, MacDougall C, Oinonen M, Polk RE. 2008. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 168:2254–2260. doi: 10.1001/archinte.168.20.2254. - DOI - PubMed
    1. Polk RE, Hohmann SF, Medvedev S, Ibrahim O. 2011. Benchmarking risk–adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis 53:1100–1110. doi: 10.1093/cid/cir672. - DOI - PubMed
    1. Kelesidis T, Braykov N, Uslan DZ, Morgan DJ, Gandra S, Johannsson B, Schweizer ML, Weisenberg SA, Young H, Cantey J, Perencevich E, Septimus E, Srinivasan A, Laxminarayan R. 2016. Indications and types of antibiotic agents used in 6 acute care hospitals, 2009–2010: a pragmatic retrospective observational study. Infect Control Hosp Epidemiol 37:70–79. doi: 10.1017/ice.2015.226. - DOI - PMC - PubMed
    1. Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. 2016. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 176:1639–1648. doi: 10.1001/jamainternmed.2016.5651. - DOI - PMC - PubMed
    1. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58:S20–S27. doi: 10.1093/cid/cit614. - DOI - PubMed

Publication types